NCT05024747View on ClinicalTrials.gov

A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2021

Conditions
Tobacco Use Disorder
Interventions
DRUG

NicoDerm CQ patch (GSK Dungarvan)

A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm\^2) surface area will be placed topically.

DRUG

NicoDerm CQ (Alza)

A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm\^2 surface area will be placed topically.

Trial Locations (1)

65802

GSK Investigational Site, Springfield

All Listed Sponsors
lead

HALEON

INDUSTRY

NCT05024747 - A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers | Biotech Hunter | Biotech Hunter